New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 20, 2012
11:08 EDTDANOY, PFE, MJN, SYUT, NSRGYDanone drops following report of raised bid for Pfizer unit
Groupe Danone (DANOY) is retreating after the French food maker increased its offer for Pfizer's (PFE) infant nutrition business to close to $11B, according to Reuters, which cited the French website WanSquare. Danone is trying to outbid Nestle (NSRGY), which was nearing a deal for the Pfizer unit last week, Reuters reported, citing unnamed sources. Pfizer's infant nutrition business is growing quickly and is strong in emerging markets, with a key position in China, Reuters added. In late morning trading, Danone dropped 27c, or 1.91%, to $13.89. Pfizer (PFE) is climbing, while Mead Johnson (MJN) and Synutra (SYUT), which also sell infant formula, advanced.
News For DANOY;PFE;MJN;SYUT;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 19, 2014
14:18 EDTDANOYFresenius, others explore bid for Danone medical nutrition unit, Reuters says
Subscribe for More Information
13:21 EDTMJN, DANOYDanone says not carrying out review on Mead Johnson takeover, Reuters says
In response to reports on Friday that French food company Danone (DANOY) was pursuing a takeover of pediatric nutrition company Mead Johnson (MJN), Danone made a statement on Sunday saying that it was not carrying out a review of a Mead Johnson takeover, says Reuters. Reference Link
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
16:17 EDTMJN, DANOYOn The Fly: Closing Wrap
Subscribe for More Information
12:57 EDTMJN, DANOYDanone to pursue takeover of Mead Johnson, sources say, Reuters reports
Subscribe for More Information
12:48 EDTMJNMead Johnson calls active on Danone will pursue takeover report
Subscribe for More Information
12:36 EDTDANOY, MJNDanone will pursue Mead Johnson takeover, sources say, Reuters reports
Subscribe for More Information
October 16, 2014
08:38 EDTPFEBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
08:08 EDTPFEActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
05:29 EDTNSRGYNestle reports FY outlook unchanged
Subscribe for More Information
05:28 EDTNSRGYNestle reports 9 month sales of CHF 66.2B
Subscribe for More Information
October 15, 2014
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
08:28 EDTDANOYDanone reports Q3 like-for-like sales up 6.9% to EU 5.42B
Danone confirmed its 2014 targets of sale growth between 4.5%-5.5%, trading operating margin stable within a range of down 20bps and up 20bps and free cash-flow of around EU 1.5B excluding exceptional items.
October 14, 2014
11:23 EDTPFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
October 10, 2014
08:39 EDTSYUTSynutra sees FY15 revenue $450M-$500M
Subscribe for More Information
08:39 EDTSYUTSynutra sees Q2 revenue $106M-$110M, Q2 net income $9M-$10M
These positive results were due to increased IMF sales at the distributor and retail channels.
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use